Ovarian cancer

Newk's Eatery Raises More Than $250,000 to Battle Ovarian Cancer

Retrieved on: 
Tuesday, December 4, 2018
RTT, Gynaecological cancer, Cafés, Newk's Eatery, Ovarian cancer, Teal, Cancer prevention, Health, Food and drink

JACKSON, Miss., Dec. 4, 2018 /PRNewswire/ --Celebrating its fifth year fighting for women battling ovarian cancer, Newk's Cares - the ovarian cancer awareness movement spearheaded by Newk's Eatery - raised over $258,000 for research of the disease.

Key Points: 
  • JACKSON, Miss., Dec. 4, 2018 /PRNewswire/ --Celebrating its fifth year fighting for women battling ovarian cancer, Newk's Cares - the ovarian cancer awareness movement spearheaded by Newk's Eatery - raised over $258,000 for research of the disease.
  • During the month of September, Newk's Eatery's iconic collectible cups turned teal, the color of Ovarian Cancer Awareness.
  • in partnership with St. Dominic Hospital to raise awareness and support of ovarian cancer prevention and treatment.
  • Along with Newk's Cares' seasonal efforts, Newk's has made a commitment to prioritize awareness of ovarian cancer in its 125 locations year-round.

Steps Through OC Launches to Provide Professional Counseling and Expert Resources for Women with Ovarian Cancer and Their Families

Retrieved on: 
Wednesday, November 28, 2018
RTT, Cancer, Ovarian cancer, Gynaecological cancer, Gynaecology, Oncology, Ovarian Cancer National Alliance

Steps Through OC provides free access to professional counseling, patient education, psychosocial support, vetted referrals and science-based resources, all customized to individual needs.

Key Points: 
  • Steps Through OC provides free access to professional counseling, patient education, psychosocial support, vetted referrals and science-based resources, all customized to individual needs.
  • Steps Through OC merges expertise in ovarian cancer science, treatment management and psychology from The Clearity Foundation , which hosts the program, and Susan Poorman Blackie Ovarian Cancer Foundation (SPB Foundation), which is a seed funder.
  • Dodson, a licensed therapist, was compelled by the opportunity to ease psychological and physical stressors for women and families confronting ovarian cancer.
  • Steps Through OC is a free, national support system of professional counseling and education with an exclusive focus on ovarian cancer.

Global Hormone Replacement Therapy (HRT) Markets 2016-2018 & 2024 - Intense Competition Marks the Global HRT Market

Retrieved on: 
Friday, November 16, 2018
Endocrine system, Medicine, Clinical medicine, Estrogens, Estranes, Menopause, Hepatotoxins, Prolactin releasers, Hormone replacement therapy, Bioidentical hormone replacement therapy, Estriol, Ovarian cancer

Bio-identical Hormones - A Natural and Safe Substitute to Synthetic HRT?

Key Points: 
  • Bio-identical Hormones - A Natural and Safe Substitute to Synthetic HRT?
  • Estriol: The Next Generation Estrogen Therapy?
  • Are Non-Hormonal Therapies A Threat to HRT?
  • New Meta-Analysis Positively Links Ovarian Cancer to Use of HRT, Albeit Modest

Wanda Diak Announces Retirement from Cancer Hope Network

Retrieved on: 
Thursday, November 15, 2018
Oncology, Gynaecological cancer, Gynaecology, Ovarian cancer, RTT

CHESTER, N.J., Nov. 15, 2018 /PRNewswire-PRWeb/ --After 22 years at the helm, Cancer Hope Network Executive Director Wanda Diak will retire December 2018.

Key Points: 
  • CHESTER, N.J., Nov. 15, 2018 /PRNewswire-PRWeb/ --After 22 years at the helm, Cancer Hope Network Executive Director Wanda Diak will retire December 2018.
  • Cancer Hope Network Support Volunteers have faced more than 80 types of cancer and speak 15 languages.
  • Following her own bout with ovarian cancer, she joined the Cancer Hope Network (Then known as CHEMOcare) in 1997 as part of a Loaned Executive program through AT&T.
  • "Cancer Hope Network has been an opportunity to fulfill a promise I made to myself during a particularly dark time of treatment," Diak recalls.

Women with a Rare Disease Take Control of Their Destiny

Retrieved on: 
Tuesday, November 6, 2018
Human reproduction, Health, Medicine, Fertility, Menopause, Menstrual cycle, Premature ovarian failure, Oncology, Poi, Ovarian cancer, Rare disease

MCLEAN, Va., Nov. 6, 2018 /PRNewswire/ -- ConoverSystems.org , Inc., an organization created and governed by women with a rare disease, announced today its strategic approach to solving the ever present problem of delivering evidence-based care to those struggling with a rare disease.

Key Points: 
  • MCLEAN, Va., Nov. 6, 2018 /PRNewswire/ -- ConoverSystems.org , Inc., an organization created and governed by women with a rare disease, announced today its strategic approach to solving the ever present problem of delivering evidence-based care to those struggling with a rare disease.
  • Young women needing care for Primary Ovarian Insufficiency (POI) have created a streamlined process by which to provide access to specialized health care for themselves and other women.
  • Individuals with rare disorders are known to have difficulty getting proper care.
  • Published reports show that approximately 50% of women with POI see three or more physicians before the condition is recognized and the diagnosis confirmed.

World Women's Health Therapeutics Market Report 2018-2025: Market Size is Expected to Reach USD 210.9 Billion - Growing Awareness and Introduction of New Drug Therapies

Retrieved on: 
Thursday, November 1, 2018
RTT, Juneau Biosciences, Biocon, Torso, Health, Ovarian cancer, Cancer, Medicine, Endometriosis, Uterus

The women's health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications.

Key Points: 
  • The women's health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications.
  • Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.
  • In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer.
  • Increasing investments by top market players are anticipated to propel the global market over the forecast period.

Study Finds Lack of Ovarian Cancer Awareness Heightens Mortality Worldwide

Retrieved on: 
Tuesday, October 30, 2018
Cancer, RTT, Ovarian cancer, Gynaecological cancer, Gynaecology, Oncology, Ovarian Cancer National Alliance

ATLANTA, Oct. 30, 2018 /PRNewswire/ -- A recently published study of more than 1,500 women shows a "woeful" lack of awareness of the symptoms, causes and treatments for ovarian cancer.

Key Points: 
  • ATLANTA, Oct. 30, 2018 /PRNewswire/ -- A recently published study of more than 1,500 women shows a "woeful" lack of awareness of the symptoms, causes and treatments for ovarian cancer.
  • Research by the World Ovarian Cancer Coalition found that two-thirds of the women surveyed did not even know about the condition before being diagnosed with the deadly disease.
  • With almost 250,000 new cases reported annually worldwide, ovarian cancer is the seventh-most common cancer diagnosis and the eighth-most common cause of female death worldwide.
  • "Thousands of women are suffering and dying of ovarian cancer because of a lack of knowledge," O'Dell said.

Global Ovarian Cancer Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, And Market Shares

Retrieved on: 
Friday, October 26, 2018
RTT, Gynaecology, Health, Medicine, Oncology, Women\'s health, Ovarian cancer, Gynaecological cancer, Cancer, Ovary, Market share, Ovarian Cancer National Alliance

The "Global Ovarian Cancer Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ovarian Cancer Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Ovarian Cancer Market and Competitive Landscape - 2018, provides comprehensive insights into Ovarian Cancer pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Ovarian Cancer market size and drug sales.
  • The research is classified into following sections - Ovarian Cancer overview with definitions, symptoms, etiology, diagnosis, treatment options; Ovarian Cancer pipeline insights covering late stage clinical trials pipeline; Ovarian Cancer prevalence trends by countries; Ovarian Cancer market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

Retrieved on: 
Saturday, October 20, 2018
Medicine, Immune system, Cancer, Immunology, Agenus, Oncology, Programmed cell death protein 1, Ovarian cancer, CTLA-4, Checkpoint inhibitor, Ipilimumab

"We have initiated expanded clinical trials designed for potential approval of our proprietary PD-1 and CTLA-4 antibodies in second line cervical cancer," said Garo Armen, Ph.D., Chairman and CEO of Agenus.

Key Points: 
  • "We have initiated expanded clinical trials designed for potential approval of our proprietary PD-1 and CTLA-4 antibodies in second line cervical cancer," said Garo Armen, Ph.D., Chairman and CEO of Agenus.
  • Data presented at ESMO is based on 76 patients treated with PD-1 (AGEN2034) as well as combination PD-1 and CTLA-4 (AGEN1884) regimens.
  • Agenus' anti-PD-1 (AGEN2034) and CTLA-4 (AGEN1884) reveal clinical activity across multiple solid tumors, including breast and gynecologic cancers such as cervical and ovarian.
  • Since the ESMO data cut-off, early evidence of clinical benefit was observed in patients with cervical cancer treated with combination AGEN2034 and AGEN1884.

Researchers, cancer patients, and philanthropists launch Count Me In, a new model of patient-partnered research to speed progress against cancer

Retrieved on: 
Thursday, October 18, 2018
Cancer, Medicine, Health, RTT, Oncology, Ovarian cancer, Colorectal cancer, Osteosarcoma, Hereditary nonpolyposis colorectal cancer, Li–Fraumeni syndrome

Count Me In allows cancer patients anywhere in the United States or Canada to easily share their medical information, personal experience, and tumor samples for genetic analysis, propelling progress against cancer.

Key Points: 
  • Count Me In allows cancer patients anywhere in the United States or Canada to easily share their medical information, personal experience, and tumor samples for genetic analysis, propelling progress against cancer.
  • One reason is that the vast majority of cancer patients receive treatment in community hospitals and clinics not at the large academic medical centers that conduct cancer research.
  • Because of this, only a fraction ever have the opportunity to contribute to research that might unlock critical insights.
  • Over the next few years, Count Me In plans to launch additional projects in all major cancer types, as well as many rare cancers, including brain cancers, osteosarcoma, pancreatic cancer, lung cancer, colorectal cancer, urinary cancer, ovarian cancer and others.